The FDA recently approved Journavx, the first groundbreaking painkiller in over two decades that could serve as a safer alternative to opioids. But there's a catch: its high cost and limited availability are putting it out of reach for many patients who desperately need it.

Editor’s Note: This isn’t just another drug approval—it’s a potential game-changer for pain management, especially amid the opioid crisis. But if most patients can’t afford or access it, the breakthrough loses its impact. It highlights the frustrating gap between medical innovation and real-world affordability.

There's finally a new non-opioid painkiller for severe pain—a big deal in the fight against addiction—but there's a catch. It's pricey, and insurance companies aren't consistently covering it, leaving many patients stuck without access.

Editor’s Note: This isn't just another medical breakthrough story—it's about how hard it is to actually get breakthroughs to the people who need them. Opioid alternatives could save lives, but if cost and insurance roadblocks keep them out of reach, we're only solving half the problem.